cAMPfield has secured $180 million in Series A funding to develop an anti-inflammatory therapy targeting inflammatory bowel diseases (IBD). The drug candidate, which originated with vTv Therapeutics, is designed to treat conditions like Crohn's disease and ulcerative colitis.
The therapy aims to offer a differentiated safety profile compared to existing IBD treatments, which often carry significant side effects. The program is in early-stage development, with preclinical data suggesting improved tolerability.
cAMPfield plans to use the proceeds to advance the candidate through Phase 1 and Phase 2 clinical trials. The company expects to file an Investigational New Drug (IND) application with the FDA within the next 18 months.
The $180M round was led by prominent investors, signaling strong interest in gut disease therapies. The IBD market, dominated by drugs like Humira and Stelara, is expected to grow to over $20 billion by 2030.
If successful, the drug could provide a new option for patients who do not respond to or cannot tolerate current therapies. However, the compound remains in early stages, and clinical failure rates for novel IBD programs are high.